Houston med-aesthetic company acquired in $550M deal

M&A

Houston-based Soliton, which has created a technology that uses sound to treat cellulite and scars, has been acquired. Photo via soliton.com

A California company has acquired Houston-based Soliton as well as its innovative device that uses sound to eliminate cellulite.

Allergan Aesthetics, an AbbVie company, has announced an agreement to acquire Soliton and its rapid acoustic pulse device RESONICTM, which recently received U.S. Food and Drug Administration clearance for the treatment of cellulite.

The company's team first developed the basis of the tool for tattoo removal and earned FDA clearance for that treatment a few years ago. Christopher Capelli and Walter Klemp co-founded Soliton in 2012.

The acquisition will take Soliton's technology to the next level, says Klemp, who serves as the company's executive chairman.

"Allergan Aesthetics' brand recognition, global footprint, track record and commitment to developing best-in-class aesthetic treatments makes the Company ideally suited to maximize the commercial potential of the RESONICTM rapid acoustic pulse technology," Klemp says in the release.

"I am proud of the passion and accomplishments of the Soliton team and thankful for the ongoing support of our investors which have culminated in this transaction," he continues. "We look forward to working with Allergan Aesthetics to ensure a successful completion of this transaction."

For Carrie Strom, president of Global Allergan Aesthetics and senior vice president at AbbVie, Soliton's solution has a great potential in the market. Soliton's clinical trial data that was submitted to the FDA showed that after a single treatment session, RESONICTM demonstrated significant improvement and strong patient satisfaction with 92.9 percent of subjects agreeing or strongly agreeing their cellulite appeared improved, per the release.

"There is a huge unmet need to address cellulite and effective treatments have been elusive and frustrating for consumers," Strom says in the release. "Soliton's technology offers a new, completely non-invasive approach with clinically-proven results to reduce the appearance of cellulite with no patient downtime.

"The addition of this technology complements Allergan Aesthetics' portfolio of body contouring treatments," she continues. "Health care providers will now have another option to address consumers' aesthetic concerns."

Brad Hauser, CEO of Soliton, previously told InnovationMap that the company's plans for 2021 included focusing on the commercialization of their product and get it into the hands of dermatologists, plastic surgeons, and other medical professionals for 25 key accounts — potentially including ones Houston — with a plan for a national rollout in 2022.

Houston-based Moleculin Biotech now has four different oncology treatment currently in trials. Getty Images

Houston cancer-fighting biotech company introduces its 4th ongoing clinical trial

health report

A Houston-based biotech company has wrapped up enrollment for its most recent clinical trial of its cancer-fighting drug.

Moleculin Biotech Inc. (Nasdaq: MBRX) has launched its fourth ongoing trial — this time focusing on Cutaneous T-Cell Lymphoma, or CTCL, treatment. The company's other three trials include treatment for glioblastoma, an aggressive brain cancer, pancreatic cancer, one of the most virulent killers in oncology, and acute myeloid leukemia, or AML.

To treat these various types of cancers, Moleculin has a several drugs it's in preclinical or clinical trials testing — most biotech companies have only one they focus on. WP1220 is the drug that will be used in this trial for topical CTCL treatment of the cancer's resulting skin lesions.

"We believe there continues to be an unmet need for an improved topical therapy for Stage I-III CTCL skin lesions," says Walter Klemp, Moleculin's chairman and CEO, in a news release, "especially one that may avoid significant unwanted side effects."

WP1220 is what's known as a p-STAT3 inhibitor. STAT3 is a transcription factor that encourages tumor development. Moleculin's technology directly attacks the tumor, but also quiets T Cells, which allows the body's own immune system to fight the cancer itself. Essentially, it works both as chemotherapy and immunotherapy.

"This proof of concept, if successful, could be an important first demonstration of a therapeutic effect in humans from such a p-STAT3 inhibitor," Klemp continues. "We are pleased with how quickly this trial reached full recruitment and we are hopeful to be able to announce results from this trial yet this year."

Klemp founded the company in 2007, and Moleculin went public in 2016. Now, with the company's four clinical trials, Moleculin is even closer to saving lives with its products.

"Notwithstanding the relatively rare nature of CTCL, we believe showing activity with one of our STAT3 inhibitors, within our WP1066 family of molecules, could be an indicator of both the value of p-STAT3 as a target and the potential for our drugs in other cancers where STAT3 is highly activated," Klemp says in the release.

From cryotherapy and NASA-inspired fitness to startup funding and biotech, this week's innovators to know are raising the bar on health tech and innovation. Courtesy photos

4 health-focused Houston innovators to know this week

Who's who

This week's innovators to know are focused on health and wellness, from a Houston-based cryotherapy franchise to the person behind funding medical device and digital health startups. We couldn't narrow these folks down to the usual three, so here are the four Houston innovators to know as we start the last week in February.

Juliana Garaizar, director of the Texas Medical Center Venture Fund

Courtesy of TMC

Juliana Garaizar has worked all around the world, and her international contacts and venture capital experience has landed her at the heart of the Texas Medical Center leading the TMC Venture Fund.

"I think TMC wants to be positioned as a strong competitor to the East and West Coasts as a point of entry for companies coming to the United States, but also for technology and commercializations from hospitals," she tells InnovationMap. "The fact that I'm already very connected to other countries — not only from the funding side but also from the research side, is really helpful."

Garaizar has her hands full running the $25 million nonprofit fund that invests around $2 million a year. Recipients, which all have a connection to TMC either through the accelerator or workspaces, receive a range between $250,000 to $500,000, and can go up to $1 million in a deal, Garaizar says. She is focused on securing deal flow for the fund before growing it more.

"In the long term, we would like to raise a bigger fun, around $100 million fund," she says. "We would need to make sure we have our deal flow ready for that, and a big part of that would be international deal flow."

Walter Klemp, chairman and CEO of Moleculin

Courtesy of Moleculin

It's pretty concerning to Walter Klemp that, while Houston has the world's largest medical center, "the tragic irony" is that other cities have far more biotech money ready to be invested.

"The Third Coast is really starved for capital," he tells InnovationMap. "What drew me into this was I was one of the few entrepreneurs that lived here that knew the ropes in terms of tapping into East and West Coast capital structures and could make that connection for them."

In 2007, chairman and CEO Walter Klemp founded Moleculin Biotech Inc. as a private company. The company has three core technologies currently being tested with some success, but the most promising is called WP1066, which uses propolis, a compound of beeswax, sap and saliva that bees produce to seal small areas of their hives, as a base. The active compound both downregulates the STAT3, a long-time Holy Grail in the cancer research world, and directly attacking the tumor, but also quieting T Cells, which allows the body's own immune system to fight the cancer itself. Essentially, it works both as chemotherapy and immunotherapy.

Jay Sutaria, founder and lead trainer of Sutaria Training & Fitness

Courtesy of ST&F

Earthbound Houstonians have a chance to use NASA training equipment thanks to Jay Sutaria's company, Sutaria Training & Fitness.

"It's exclusive access to the equipment that is not available openly in Houston," Sutaria tells InnovationMap. "NASA is a reference for us to become better trainers."

Sutaria founded his company in 2011 while he was a student at the University of Houston, and the company now operates with two trainers. His clients include professional athletes such as D.J. Augustin (Orlando Magic, NBA); and Tim Frazier (New Orleans Pelicans, NBA), however, Sutaria and his team offer professional personal training services to any type of athlete.

Kyle Jones, COO of iCRYO

Courtesy of iCryo

Kyle Jones says he's always known he was destined for entrepreneurship, and when he came across the potential of cryotherapy while working at a physical therapist office, he knew it was a scalable business.

He opened his first location of iCRYO in League City in 2015. Now the company is

Jones says he used the location to work out the kinks of his business model, since he didn't really have much to model after. One thing that was most important to Jones, with his PT background, was safety of the patients. He cared about this more than making money, he says.

"I knew first and foremost the one thing that the cryotherapy space didn't have was a certification program, which is kind of terrifying to me," Jones tells InnovationMap. "Any therapy has some type of schooling or certification — massage therapy and acupuncture both have it. Cryotherapy even to date does not a certification to it."

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston universities climb the ranks on annual list of most patents issued

top 100

The University of Houston and Rice University have claimed spots on the National Academy of Inventor's Top 100 U.S. Universities Granted Utility Patents.

The list is based on data obtained from the U.S. Patent and Trademark Office and ranks U.S. academic institutions that are advancing innovation by the number of utility patents issued in the prior year.

Utility patents are among the world’s most valuable assets because they give inventors exclusive commercial rights to produce and use their technology. The universities ranked on the list collectively hold nearly 6,500 patents.

“In the ever-evolving innovation landscape, it is imperative that the U.S. is remaining competitive and at the forefront of today’s emerging research and technologies,” Paul R. Sanberg, president of the NAI, said in a news release. “Ensuring the security of intellectual property through patenting is a crucial component to this and allows those innovations to be effectively moved to market, where they can create valuable societal and economic impact. The Top 100 U.S. list celebrates U.S. universities and their inventive staff and faculty for their dedication in ensuring their innovations and IP are protected.”

The University of Houston System came in at No. 62 with 34 patents, and Rice University claimed the No. 68 spot with 30 patents.

Both universities climbed up the rankings this year. Last year, UH was ranked No. 63 with 27 patents. Rice climbed an impressive 26 spots this year, after ranking No. 94 with 14 patents issued in 2023.

“Granted U.S. utility patents can tremendously help in commercializing the technologies covered by such patents by attracting industry investment and commercial partners on a global level,” Neha Malik, assistant director for intellectual property management in Rice's Office of Technology Transfer, said in a release. “Advancing in this list memorializes Rice’s commitment to support research programs of Rice faculty by generating a path for the university to bring its research to the marketplace.”

Other Texas universities on the list include:

No. 3 University of Texas System (234 patents)
No. 35 The Texas A&M System (61 patents)
No. 73 Texas Tech University System (25 patents)
No. 80 Baylor University (20 patents)

The University of California (540 patents) claimed the No. 1 spot again this year, followed by the Massachusetts Institute of Technology (295 patents), which also placed second for 2024.

First large-scale affordable housing project of 3D-printed homes rises in Houston

Building Blocks

What’s being promoted as the world’s first large-scale affordable housing development built using 3D technology is taking shape in Houston.

Houston-based 3D construction company HiveASMBLD has teamed up with Houston-based Cole Klein Builders and the City of Houston on the Zuri Gardens project. Located near Hobby Airport on Martindale Road, the first 3D-printed home at Zuri Gardens is set to be completed in October.

“Zuri Gardens was born from the frustration of watching hardworking families get priced out of safe, resilient housing. We knew there had to be a better way — and with this project, we’re proving that there is,” says Vanessa Cole, co-founder of Cole Klein Builders.

“By combining visionary design, advanced construction technology, and powerful partnerships, we’re building more than just homes — we’re creating a blueprint for the future of equitable homeownership in Houston and beyond.”

The development is being created for households earning up to 120 percent of the median income in the Houston metro area. For a four-member household in the Houston area, the 120 percent limit in 2025 is $121,300, as set by the U.S. Department of Housing and Urban Development (HUD).

The 13-acre Zuri Gardens development will feature 80 energy-efficient homes averaging 1,360 square feet. Prices will be in the mid to high $200s. The homes will qualify for up to $125,000 in down payment assistance from the City of Houston.

HiveASMBLD will print two different home designs, each with two-bedroom and two-and-a-half bathroom configurations, along with an office/flex space and a covered patio.

Zuri Gardens home model Houston Courtesy rendering

“The community we envision for Zuri Gardens is modern, safe, and one that residents will be proud to call home. When completed using HiveASMBLD’s innovative technology, this 3D-printed multifamily community will exemplify the future of residential affordable living,” says Timothy Lankau, founder and co-CEO of HiveASMBLD.

Developments like Zuri Gardens are popping up around the country.

“3D-printed homes are revolutionizing the construction industry by making home builds faster, cheaper, and more sustainable,” according to The Zebra, an Austin-based insurance marketplace. “In less than 24 hours, 3D printers can print the foundation and walls for a small home at a fraction of the cost of typical construction.”

U.S. News & World Report explains that unlike a traditional home, a 3D-printed home is printed in place, “just like you’d print a knickknack on your home 3D printer. Layer by layer, proprietary concrete blends are used to build the wall systems of the home in any type of design that a builder can imagine.”

Texas is home to several trailblazing 3D-printed projects.

In the U.S., the first 3D-printed home was built in 2018 in Austin, and the first 3D-printed multistory home was completed in 2023 in Harris County’s Spring Branch neighborhood. Meanwhile, the world’s largest neighborhood of 3D-printed homes is located in the Austin suburb of Georgetown.

Grand View Research predicts the global market for 3D-printed construction will approach $4.2 billion by 2030.

---

This article originally appeared on CultureMap.com.

Houston tech company secures $450M NASA contract

space deal

NASA’s Johnson Space Center awarded Houston-based aerospace technology and engineering services company Barrios Technology the Mission Technical Integration Contract (MTIC).

The two-year contract is worth $450 million and will begin Oct. 1, 2025.

Barrios will provide technical and management support to some of NASA’s human spaceflight programs, which include the Orion and Gateway programs, the International Space Station (ISS) and possibly more human spaceflight initiatives.

The contract represents a continuation of Barrios’ Human Space Flight Technical Integration Contract (HSFTIC), which has been in effect since 2020.

“We are incredibly proud to have been selected by NASA to continue working side by side with them in shaping the future of human space exploration,” Kelly Page, president of Barrios Technology, said in a news release.

The contract also includes support for program, business, configuration and data management, information technology, systems engineering and integration, mission integration, safety and mission assurance, and operations according to Barrios.

Barrios will be supported by subcontractors ARES Technical Services Corp., Booz Allen Hamilton, Intuitive Machines, Summit Technologies & Solutions, and TechTrans International (TTI).

“This award is a testament to the passion, hard work, and extraordinary value that our Barrios family brings every single day,” Page added in the release. “This is not just another contract award—it is the continuation of a generational commitment to our NASA customers and their critical missions.”

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME